84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02523092 (ClinicalTrials.gov) | October 2020 | 10/8/2015 | Use of CXCL9 as a Biomarker of Acthar Efficacy | Use of CXCL9 as a Biomarker of Acthar Efficacy | Sarcoidosis | Drug: Acthar gel | University of California, San Francisco | Mallinckrodt | Not yet recruiting | 18 Years | 65 Years | All | 14 | Phase 4 | United States |
2 | NCT03320070 (ClinicalTrials.gov) | February 21, 2018 | 20/10/2017 | Acthar Gel in Participants With Pulmonary Sarcoidosis | A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Acthar Gel;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | 90 Years | All | 55 | Phase 4 | United States |
3 | NCT02725177 (ClinicalTrials.gov) | July 2016 | 11/3/2016 | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis;Panuveitis;Anterior Uveitis | Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension | The Cleveland Clinic | Mallinckrodt | Recruiting | 18 Years | 99 Years | All | 20 | N/A | United States |
4 | NCT02298491 (ClinicalTrials.gov) | May 2016 | 14/11/2014 | CNS Sarcoidosis and Acthar Gel | Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel | CNS Sarcoidosis | Drug: H.P. Acthar Gel | University of Maryland, Baltimore | Mallinckrodt | Completed | N/A | N/A | All | 4 | Phase 4 | United States |
5 | NCT02348905 (ClinicalTrials.gov) | March 2015 | 20/6/2014 | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | Sarcoidosis;Cutaneous Sarcoidosis | Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly. | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
6 | NCT02155803 (ClinicalTrials.gov) | February 2015 | 30/5/2014 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | Sarcoidosis;Hypercalcemia Due to Sarcoidosis | Drug: ACTHAR Gel (adrenocorticotropic hormone) | Albany Medical College | NULL | Not yet recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States |
7 | NCT02188017 (ClinicalTrials.gov) | June 2014 | 24/4/2014 | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) | ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) | Sarcoidosis;Pulmonary Sarcoidosis | Drug: Acthar gel | University of Cincinnati | Mallinckrodt | Recruiting | 18 Years | 90 Years | Both | 20 | Phase 4 | United States |